Control of SIV Rebound Through Structured Treatment Interruptions During Early Infection

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Control of SIV Rebound Through Structured Treatment Interruptions During Early Infection

Science (www.sciencemag.org) (11/24/00) Vol. 290, No. 5496, P. 1591
Lori, Franco; Lewis, Mark G.; Xu, Jinqing; et al.

Researchers studying macaques with acute SIV infection found that highly active antiretroviral therapy (HAART) and fixed- schedule structured treatment interruption (STI-HAART) were able to suppress the animals' viral load. STI-HAART consisted of alternating three weeks on and three weeks off drug therapy. In the treatment interruption cohort, T cell virus- specific immune response (VIR) and control of viral rebound rose during later interruptions. Meanwhile in the macaques receiving continuous HAART, there was no VIR increase and SIV rebounded after permanent treatment withdrawal. The researchers concluded that fixed-schedule STI-HAART may be an effective alternative to continuous HAART, although more studies are needed.
001206
AD002167

Copyright © 2000 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.